To the best of our knowledge, this is the first study regarding systemic treatment consisting of anti-PD-1 antibody plus chemotherapy in patients with advanced ICC and investigating the efficacy and safety of the combined therapy. Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.